Future research could focus on combining ME2 inhibitors with other chemotherapeutic agents, such as cytarabine and daunorubicin or idarubicin, or with FLT3 or glutaminase inhibitors, to improve the overall efficacy of AML therapy and delay the recurrence of the disease due to chemoresistance. The gene discussed is GLS; the disease is acute myeloid leukemia.